Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Enroll crawled date : 2022 - 04 - 28 save search
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
VAXX | $0.2696 -43.37% -84.53% 5.6M
|
|
| O: -1.94%
H: 8.76%
C: 6.5%
ub-312 disease trial enroll phase 1
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
ABVC | $1.04 5.04% 2.93% 310K
|
Wholesale Trade
|
| O: 0.87%
H: 2.16%
C: 2.16%
biopharma adhd enroll
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Published: 2022-04-28 (Crawled : 13:00) - biospace.com/
ZYME | $8.71 -1.58% -1.49% 720K
|
Health Technology
|
| O: 0.0%
H: 1.84%
C: 1.43%
treatment cancer enroll her2- her2
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.